Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Moxonidine drug can improve heart function and reduce blood pressure

Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the imidazoline receptors in the cardiovascular center of the brainstem.

23 Apr 2012

SUMO protein regulates transfer of information between nerve cells in the brain

A key protein, which may be activated to protect nerve cells from damage during heart failure or epileptic seizure, has been found to regulate the transfer of information between nerve cells in the brain. The discovery, made by neuroscientists at the University of Bristol and published in Nature Neuroscience and PNAS, could lead to novel new therapies for stroke and epilepsy.

23 Apr 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

21 Apr 2012

Updated results from CircuLite’s Synergy miniature ventricular support system clinical study

CircuLite, Inc. today announced that updated clinical data related to the Synergy miniature ventricular support system was presented in two oral presentations and one poster session at the International Society for Heart and Lung Transplantation's 32nd Annual Meeting and Scientific Sessions (ISHLT) in Prague, Czech Republic.

21 Apr 2012

UCSD named among 100 Top Hospitals by Thomson Reuters

UC San Diego Medical Center, located in Hillcrest, has been named one of the nation's 100 Top Hospitals by Thomson Reuters. Ranked among the country's major teaching hospitals, the Medical Center was also one of twelve hospitals to receive the Everest Award. This award honors hospitals that have achieved both the highest current performance and the fastest long-term improvement over a five-year period in Reuter's national benchmarking study.

19 Apr 2012

Testosterone may help heart failure patients: Study

The researchers used testosterone patches and injections that improved the breathing and exercise abilities of people with heart failure, a chronic inability of the heart to pump enough blood to the rest of the body. Although most of the study participants were men, the researchers said the results would likely apply to women as well, through much smaller doses of testosterone.

18 Apr 2012

Viewpoints: The missing debate on women; The true cost of care; Fair wages for home health aides

The Centers for Disease Control and Prevention just reported that the nation's teen pregnancy rate is at an all-time low. Increased contraceptive use appears to have played a significant role in the decline. The Guttmacher Institute estimates that without Title X services, hundreds of thousands more teenagers would become pregnant every year. Why does GOP presidential candidate Mitt Romney think eliminating the federal money for family planning - $327 million annually - is wise?

17 Apr 2012

St. Jude Medical's Ellipse ICD receives CE Mark Approval

St. Jude Medical, Inc., a global medical device company, today announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator (ICD). Designed with feedback from more than 200 physicians from around the world, the Ellipse ICD provides the benefits of advanced features and power in the industry's smallest high-energy ICD.

16 Apr 2012

FDA approves HUD designation for SynCardia temporary Total Artificial Heart for destination therapy

SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the U.S. Food and Drug Administration has approved a Humanitarian Use Device (HUD) designation for the SynCardia temporary Total Artificial Heart to be used for destination therapy in addition to its current PMA approval as a bridge to transplant.

12 Apr 2012

C3BS' new production facilities in Mont-Saint-Guibert granted GMP Certification

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has been granted Good Manufacturing Practice (GMP) Certification for its new production facilities in Mont-Saint-Guibert.

12 Apr 2012

AstraZeneca introduces DUTOPROL for hypertension

AstraZeneca today announced the availability of DUTOPROL (metoprolol succinate extended release/hydrochlorothiazide) Tablets, the first and only once-daily antihypertensive agent that contains the active ingredient of TOPROL-XL (metoprolol succinate) plus a low-dose diuretic that provides proven blood pressure lowering at 24 hours.

12 Apr 2012

Study: Stem cells from pelvic bone marrow may help hearts beat stronger

Stem cells from the pelvic bone may help hearts beat stronger. Doctors and other clinicians at the Orlando Health Heart Institute are researching the use of stem cells from pelvic bone marrow to restore tissue and improve heart function after muscle damage from heart attacks.

12 Apr 2012

ST2 more specific than BNP for heart failure diagnosis

Critical Diagnostics today announced publication in the latest issue of the Journal of Heart Failure results of a study involving 995 patients who presented to the emergency room (ER) with chest pain. The study concluded that in this undifferentiated, symptomatic patient population ST2 was more specific for acute heart failure than BNP and that ST2 is independently predictive of future death and/or heart failure and has incremental utility in combination with BNP.

12 Apr 2012

Losartan may not increase risk of all-cause mortality in heart failure patients

Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.

11 Apr 2012

SomaLogic, HUNT Biosciences partner to advance clinical use of cardiovascular biomarkers

HUNT Biosciences and SomaLogic, Inc., today announced a new collaboration to advance the clinical use of protein biomarkers, with an initial focus on the validation of biomarkers for the prediction of cardiovascular events such as strokes, heart attacks, and heart failure.

11 Apr 2012

Study reveals difficulties in self-management of diabetes

A new study from researchers at Queen Mary, University of London reveals the many difficulties faced by people with diabetes in self-managing their disease.

11 Apr 2012

FDA approves Medtronic’s expanded indication for implantable CRT-D devices

Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) devices.

From Medtronic 11 Apr 2012

Boston Scientific receives European CE Mark approval for INGENIO family of pacemakers

Boston Scientific Corporation announces CE Mark approval and European market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers.

11 Apr 2012

Fish oil not as beneficial for the heart as thought: Study

Fish oil, a combination of omega-3 fatty acids that has attracted much research on its effects on heart health. So far, the evidence has been inconclusive -- some studies have found fish oil has been major in preventing heart attacks, strokes and sudden cardiac death, while others have found fish oil has no benefits at all.

10 Apr 2012

Lee's Pharma licenses rights to commercialize PL2200 Aspirin in China

PLx Pharma Inc, a Houston based pharmaceutical company developing gastrointestinal (GI) safer drugs has licensed to Lee's Pharmaceutical Holdings Limited (Lee's Pharma) the rights to register and commercialize in China, Hong Kong and Macau the PL2200 Aspirin, a GI safer aspirin product currently in development in the US, for prevention of cardiovascular diseases. Cardiovascular is one of the focus areas of Lee's Pharma.

10 Apr 2012